Glaukos Corp (GKOS) Stock AnalysisGKOSGlaukos Corp

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Glaukos Corp (GKOS) is a good buy right now due to its current price of $165.69, which is below the average analyst price target of $202, suggesting a potential upside of approximately 21.8%. Additionally, the company's gross margin has improved to 81.67%, indicating strong profitability potential. However, a key risk is the negative sentiment from insider selling, which has increased by 126.48% recently, potentially impacting investor confidence.

10 analysts cover GKOS: 10 rate it Buy, 0 Hold and 0 Sell. The average price target is 127.08.